Biotech Runners: Zalicus Inc. (NASDAQ: ZLCS), Amgen Inc. (NASDAQ:AMGN)

Stamford, CT -- (SBWIRE) -- 03/08/2013 -- OTC Stock Picks is engaged in providing the most up to date and useful information on Best Penny Stocks poised to breakout. Our newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. These are the awesome penny stocks that the ‘underground penny stock experts’ brag about in our penny stock blogs

Zalicus Inc. NASDAQ:ZLCS a biopharmaceutical firm that creates and develops novel treatments for patients suffering from pain, on Thursday announced financial results for the fourth quarter and year concluded on December 31, 2012.

Experts at MLV Caital lifted their price target on stock of Zalicus ZLCS from $0.50 to $0.75 in a research report given to clients and investors on Thursday. The firm presently has a “hold” rating on the stock.

How exerts reacted towards Zalicus stock? Find out here

Experts at Zacks reiterated a “neutral” rating on stock of Zalicus in a research note to investors on Wednesday.
They now possess a $1.00 price target on the shares of Zalicus. Independently, experts at Oppenheimer reiterated an “outperform” rating on stock of Zalicus in a research note to investors on Wednesday.
Merck Co. tapped previous Amgen Inc. NASDAQ:AMGN executive Roger M. Perlmutter to manage Merck's drug research-and-development wing, substituting Peter S. Kim, who is retiring.

The management change arrives at a crucial time for Merck's R&D engine, which is under stress to produce flourishing new products to help compensate sales lost to generic rivalry for older drugs. Dr. Kim's decade long period contained some huge product victories, but more lately Merck has had many R&D delays.
How stock price of Amgen responded to such move by Merck? Find in this report
Amgen, Inc NASDAQ:AMGN shares were trading just above the trend line as the stock was recently trading at 0.02% to $92.97.

About OTC Stock Picks

The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.

Disclaimer
OTC Stock Picks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.